• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?

作者信息

Patrì Angela, Fabbrocini Gabriella

机构信息

Section of Dermatology and Venereology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.

Section of Dermatology and Venereology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.

出版信息

J Am Acad Dermatol. 2020 Jun;82(6):e221. doi: 10.1016/j.jaad.2020.04.017. Epub 2020 Apr 10.

DOI:10.1016/j.jaad.2020.04.017
PMID:32283237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7146719/
Abstract
摘要

相似文献

1
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?羟氯喹啉和伊维菌素：用于新冠病毒化学预防和治疗的协同组合？
J Am Acad Dermatol. 2020 Jun;82(6):e221. doi: 10.1016/j.jaad.2020.04.017. Epub 2020 Apr 10.
2
Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.COVID-19大流行期间的紧急使用授权：羟氯喹用于疫苗授权和批准的经验教训。
JAMA. 2020 Oct 6;324(13):1282-1283. doi: 10.1001/jama.2020.16253.
3
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.氯喹或羟氯喹用于预防2019冠状病毒病。
Lancet Infect Dis. 2020 Oct;20(10):1118. doi: 10.1016/S1473-3099(20)30296-6. Epub 2020 Apr 17.
4
Hydroxychloroquine prophylaxis for COVID-19 contacts in India.印度针对新冠病毒病接触者的羟氯喹预防措施
Lancet Infect Dis. 2020 Oct;20(10):1118-1119. doi: 10.1016/S1473-3099(20)30313-3. Epub 2020 Apr 17.
5
Chloroquine as a prophylactic agent against COVID-19?氯喹作为 COVID-19 的预防药物？
Int J Antimicrob Agents. 2020 Jun;55(6):105980. doi: 10.1016/j.ijantimicag.2020.105980. Epub 2020 Apr 12.
6
Audio Interview: Diagnosis and Early Treatment of Covid-19.音频访谈：新型冠状病毒肺炎的诊断与早期治疗
N Engl J Med. 2020 Jun 4;382(23):e103. doi: 10.1056/NEJMe2021023.
7
A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.羟氯喹维持治疗期间突破性 COVID-19 感染 1 例
J Korean Med Sci. 2020 Jun 22;35(24):e231. doi: 10.3346/jkms.2020.35.e231.
8
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.新型冠状病毒肺炎防治：氯喹和羟氯喹临床药理学的批判性分析。
PLoS Med. 2020 Sep 3;17(9):e1003252. doi: 10.1371/journal.pmed.1003252. eCollection 2020 Sep.
9
Internet Searches for Unproven COVID-19 Therapies in the United States.互联网上对未经证实的新冠病毒治疗方法的搜索情况。
JAMA Intern Med. 2020 Aug 1;180(8):1116-1118. doi: 10.1001/jamainternmed.2020.1764.
10
Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2.揭示羟氯喹在新型冠状病毒肺炎中的证据
Crit Care. 2020 Apr 28;24(1):182. doi: 10.1186/s13054-020-02894-7.

引用本文的文献

1
A comparative parasitological, histopathological, and proteomic analysis of infected mice treated with ivermectin and praziquantel.对用伊维菌素和吡喹酮治疗的感染小鼠进行的寄生虫学、组织病理学和蛋白质组学比较分析。
Front Vet Sci. 2025 Jul 29;12:1646155. doi: 10.3389/fvets.2025.1646155. eCollection 2025.
2
Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.探索新冠病毒治疗领域：揭示关于美国食品药品监督管理局批准药物、疫苗接种目标及新兴策略的新观点
Molecules. 2024 Nov 25;29(23):5564. doi: 10.3390/molecules29235564.
3
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.COVID-19治疗潜在药物和疫苗的临床前与临床研究：近期更新的综合综述
Clin Pathol. 2024 Jul 26;17:2632010X241263054. doi: 10.1177/2632010X241263054. eCollection 2024 Jan-Dec.
4
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
5
The practice of using repurposed medications as chemoprophylaxis for COVID-19 by healthcare workers in a tertiary hospital in Southern Nigeria.尼日利亚南部一家三级医院的医护人员将已上市药物重新用于 COVID-19 化学预防的做法。
Afr Health Sci. 2023 Sep;23(3):406-411. doi: 10.4314/ahs.v23i3.47.
6
The practice of using repurposed medications as chemoprophylaxis for COVID-19 by healthcare workers in a tertiary hospital in Southern Nigeria.在尼日利亚南部一家三级医院，医护人员将已上市药物重新用于 COVID-19 化学预防的做法。
Afr Health Sci. 2023 Jun;23(2):37-42. doi: 10.4314/ahs.v23i2.5.
7
Redox Status Is the Mainstay of SARS-CoV-2 and Host for Producing Therapeutic Opportunities.氧化还原状态是严重急性呼吸综合征冠状病毒2（SARS-CoV-2）以及产生治疗机会的宿主的关键所在。
Antioxidants (Basel). 2022 Oct 19;11(10):2061. doi: 10.3390/antiox11102061.
8
Clinical characteristics and laboratory parameters associated with the risk of severe COVID-19 in patients from two hospitals in Northeast Brazil.与巴西东北部两家医院的 COVID-19 重症患者风险相关的临床特征和实验室参数。
Rev Soc Bras Med Trop. 2022 Sep 26;55:e0119. doi: 10.1590/0037-8682-0119-2022. eCollection 2022.
9
Can anti-parasitic drugs help control COVID-19?抗寄生虫药物能帮助控制新冠病毒吗？
Future Virol. 2022 Mar. doi: 10.2217/fvl-2021-0160. Epub 2022 Mar 18.
10
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.一项关于全球针对 SARS-CoV-2 干预措施的系统评价：从药物再利用到莫努匹韦批准。
Drug Des Devel Ther. 2022 Mar 15;16:685-715. doi: 10.2147/DDDT.S354841. eCollection 2022.

本文引用的文献

1
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
2
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.COVID-19：建议检查羟氯喹预防感染和进展的效果。
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670. doi: 10.1093/jac/dkaa114.
3
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
4
Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo.伊维菌素抑制伪狂犬病病毒进入细胞核的 DNA 聚合酶 UL42 和病毒在体外和体内的增殖。
Antiviral Res. 2018 Nov;159:55-62. doi: 10.1016/j.antiviral.2018.09.010. Epub 2018 Sep 26.
5
Treatment of Human Scabies with Oral Ivermectin. Eczematous Eruptions as a New Non-Reported Adverse Event.口服伊维菌素治疗人类疥疮。湿疹样皮疹作为一种新的未报告的不良事件。
Actas Dermosifiliogr. 2017 Sep;108(7):643-649. doi: 10.1016/j.ad.2017.02.011. Epub 2017 Apr 3.